Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "In 2022, Amicus remained steadfast in our mission to transform the lives of people living with rare diseases with excellent progress made across our strategic priorities. The Galafold business remained very strong last year, delivering double-digit operational revenue growth and finishing the year with over 2,000 patients on Galafold. We continue to expect robust growth again for 2023 driven by patient demand across the globe for this precision medicine for Fabry disease. In Pompe disease, we eagerly anticipate multiple AT-GAA regulatory approvals in key geographies including the EU, U.K., and U.S. following completion of the FDA inspection, and look forward to launching our second commercial product. We remain excited for the opportunity to offer a new and innovative treatment option, one that we believe has the potential to be the new standard of care, to people living with Pompe disease around the world. We believe we have the opportunity to deliver significant value for our shareholders as Amicus transforms into a leading global rare disease biotechnology company with two innovative therapies that can make a significant impact on the lives of people living with Fabry disease and Pompe disease."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Amicus receives positive CHMP opinion for Pombiliti for LOPD
- Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
- Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference